RNA:NSD-Avidity Biosciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 42.33

Change

0.00 (0.00)%

Market Cap

USD 5.00B

Volume

0.91M

Analyst Target

USD 43.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.71B
SMMT Summit Therapeutics PLC

N/A

USD 15.35B
PCVX Vaxcyte Inc

N/A

USD 14.00B

ETFs Containing RNA

GNOM Global X Genomics & Biote.. 5.56 % 0.00 %

N/A

USD 0.08B
GNOG:LSE Global X Genomics & Biote.. 5.53 % 0.00 %

N/A

USD 6.06M
GN0M:XETRA Global X Genomics & Biote.. 5.43 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 5.43 % 0.00 %

N/A

USD 6.06M
SURI Simplify Propel Opportuni.. 3.41 % 0.00 %

N/A

N/A
SBIO ALPS Medical Breakthrough.. 3.27 % 0.50 %

N/A

USD 0.11B
DXSP:F Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

N/A

N/A
MOON 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 367.73% 73% C 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 367.73% 73% C 88% B+
Trailing 12 Months  
Capital Gain 563.48% 76% C+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 563.48% 76% C+ 89% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 16.71% N/A N/A 75% C
Dividend Return 16.71% N/A N/A 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 112.63% N/A N/A 16% F
Risk Adjusted Return 14.84% N/A N/A 50% F
Market Capitalization 5.00B 95% A 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector